People who take Ozempic and Wegovy to lose weight are at greater risk of severe stomach injuries such as gastroparesis, gastric obstruction and stomach paralysis, a new study says.
These drugs are now the target of a growing number of lawsuits against manufacturers Novo Nordisk and Eli Lilly for failing to adequately warn consumers. The Big Pharma blockbusters were intended to be used for diabetes treatment, but they are being used off-label by hundreds of thousands of Americans who are trying to lose weight.
Study shows dramatic increase in risk of injury for weight loss drugs
A new study in the journal JAMA shows the following increased risks for users of the so-called glucagon-like peptide 1 (GLP-1) agonists:
Pancreatitis – 9 fold increased risk
Bowel obstruction – 4 fold increased risk
Gastroparesis – 3.67 fold increased risk
The lawyers at Alex Davis Law Office already represent consumers with these injuries who took Ozempic, Wegovy and a similar injected drug called Mounjaro. To qualify for a lawsuit, you must be no more than 72 years old and have taken one of the three drugs within 30 days of your injury. The main injury claims in the lawsuits are for gastroparesis, gastric obstruction and stomach paralysis. Those conditions are not included in the current version of the warning label for Ozempic. Other conditions, such as pancreatitis, are included in the drug’s patient safety guide.
Free Weight Loss Drug Lawsuit Consultation
If you want to learn more about Ozempic, Wegovy and Mounjaro injury claims, call Alex Davis Law at 502-882-6000 for a free consultation or send an email to alex@acdavislaw.com.
